Metabolic syndrome-related factors as possible targets for lower urinary tract symptoms in Korean males

References

• Speakman M, Kirby R, Doyle S, et al. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115(4):508–519.
   PubMed Web of Science ®Google Scholar
• Calogero AE, Burgio G, Condorelli RA, et al. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019;22(1):12–19.
   PubMed Web of Science ®Google Scholar
• Partin AW, Oesterling JE, Epstein JI, et al. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 1991;145(2):405–409.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20 Suppl 3:s11–s18.
   PubMed Web of Science ®Google Scholar
• Gacci M, Vignozzi L, Sebastianelli A, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 2013;16(1):101–106.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Zhang Y, Tan J, et al. The association between metabolic syndrome and lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males: evidence based on propensity score matching. Transl Androl Urol. 2021;10(1):384–396.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Rastrelli G, Corona G, et al. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 2014;37(4):313–322.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park YW, Lee SW. The relationships between thyroid hormone levels and lower urinary tract symptoms/benign prostatic hyperplasia. World J Mens Health. 2019;37(3):364–371.
   PubMedGoogle Scholar
• Iwen KA, Schroder E, Brabant G. Thyroid hormones and the metabolic syndrome. Eur Thyroid J. 2013;2(2):83–92.
   PubMedGoogle Scholar
• Chung GE, Yim JY, Kim D, et al. Nonalcoholic fatty liver disease is associated with benign prostate hyperplasia. J Korean Med Sci. 2020;35(22):e164.
   PubMed Web of Science ®Google Scholar
• Eren H, Horsanali MO. The independent association of non-alcoholic fatty liver disease with lower urinary tract symptoms/benign prostatic hyperplasia and erectile function scores. BJU Int. 2019;124(2):329–335.
   PubMed Web of Science ®Google Scholar
• Sebastianelli A, Gacci M. Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus. 2018;4(1):25–27.
   PubMedGoogle Scholar
• Ohgaki K, Hikima N, Horiuchi K, et al. Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and international prostate symptom score. Urology. 2011;77(6):1432–1438.
   PubMed Web of Science ®Google Scholar
• Park YW, Kim SB, Kwon H, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology. 2013;82(3):674–679.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1–6.
   PubMed Web of Science ®Google Scholar
• Kolman C, Girman CJ, Jacobsen SJ, et al. Distribution of post-void residual urine volume in randomly selected men. J Urol. 1999;161(1):122–127.
   PubMed Web of Science ®Google Scholar
• Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745–750.
   PubMed Web of Science ®Google Scholar
• Eom CS, Park JH, Cho BL, et al. Metabolic syndrome and accompanying hyperinsulinemia have favorable effects on lower urinary tract symptoms in a generally healthy screened population. J Urol. 2011;186(1):175–179.
   PubMed Web of Science ®Google Scholar
• Yang TK, Hsieh JT, Chen SC, et al. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. Urology. 2012;80(5):1093–1097.
   PubMed Web of Science ®Google Scholar
• Shin S, Kim SA, Ha J, et al. Sugar-Sweetened beverage consumption in relation to obesity and metabolic syndrome among Korean adults: a cross-sectional study from the 2012(-)2016 Korean National Health and Nutrition Examination Survey (KNHANES). Nutrients. 2018;10(10):1467.
   Web of Science ®Google Scholar
• Kim M-h, Lee S-h, Shin K-S, et al. The change of metabolic syndrome prevalence and its risk factors in Korean adults for decade: Korea National Health and Nutrition Examination Survey for 2008–2017. Korean J Fam Pract. 2020;10(1):44–52.
   Google Scholar
• Kim DK, Park JJ, Yang WJ, et al. Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea: a nationwide population-based cohort study. Prostate Int. 2021;9(4):215–220.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212(1):71–84.
   PubMed Web of Science ®Google Scholar
• Liu Z, Liu J, Shi X, et al. Dynamic alteration of serum testosterone with aging: a cross-sectional study from Shanghai, China. Reprod Biol Endocrinol. 2015;13(111):111.
   PubMedGoogle Scholar
• Park SG, Yeo JK, Cho DY, et al. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. Aging Male. 2018;21(1):55–59.
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33(2):351–375, table of contents.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Zhang Y, Zhang F, et al. Prevalence and associated factors of metabolic syndrome in Chinese middle-aged and elderly population: a national cross-sectional study. Aging Male. 2021;24(1):148–159.
   PubMed Web of Science ®Google Scholar
• Vesely S, Knutson T, Damber JE, et al. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2003;37(4):322–328.
   PubMed Web of Science ®Google Scholar
• Fowke JH, Motley SS, Cookson MS, et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis. 2007;10(2):137–142.
   PubMed Web of Science ®Google Scholar
• Park JH, Cho BL, Kwon HT, et al. Effect of body mass index and waist circumference on prostate specific antigen and prostate volume in a generally healthy Korean population. J Urol. 2009;182(1):106–110; discussion 110–111.
   PubMed Web of Science ®Google Scholar
• Li J, Peng L, Cao D, et al. The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis. Aging Male. 2020;23(5):1388–1399.
   PubMed Web of Science ®Google Scholar
• Russo GI, Castelli T, Urzi D, et al. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and meta-analysis. Aging Male. 2015;18(4):207–216.
   PubMed Web of Science ®Google Scholar
• Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070–18091.
   PubMed Web of Science ®Google Scholar
• Yim JY, Kim J, Kim D, et al. Serum testosterone and non-alcoholic fatty liver disease in men and women in the US. Liver Int. 2018;38(11):2051–2059.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–1327.
   PubMed Web of Science ®Google Scholar
• Lee D, Koo KC, Yoo JW, et al. Effect of systemic atherosclerosis on overactive bladder symptoms in men with benign prostatic hyperplasia. Low Urin Tract Symptoms. 2022;14(1):35–40.
   PubMed Web of Science ®Google Scholar
• Nomiya M, Andersson KE, Yamaguchi O. Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Int J Urol. 2015;22(1):40–46.
   PubMed Web of Science ®Google Scholar
• Mathieu P, Pibarot P, Despres JP. Metabolic syndrome: the danger signal in atherosclerosis. Vasc Health Risk Manag. 2006;2(3):285–302.
   PubMedGoogle Scholar
• Yazici O, Narter F, Erbin A, et al. Effect of endothelial dysfunction on the pathogenesis of urolithiasis in patients with metabolic syndrome. Aging Male. 2020;23(5):1082–1087.
   PubMed Web of Science ®Google Scholar
• Cakir SS, Ozcan L, Polat EC, et al. Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome. Aging Male. 2020;23(5):538–543.
   PubMed Web of Science ®Google Scholar